THE SAME-CELL CAUSALITY COMPANY
A World Where Cures Are Built, Not Discovered. Beyond Correlation.
Single-Cell Biology captures what cells are. Same-Cell Biology reveals what they become and why. Precise engineering shapes what comes next.
SAME-CELL BIOLOGY
Turn Same-Cell evidence into better-informed therapeutic decisions.
Traditional high-dimensional molecular profiling in biology hits the same wall: to measure a cell, you have to kill it, so you never see what it would have become. In genome engineering, conventional delivery methods perturb the cell beyond the intended genetic edit, affecting viability, fitness, or cellular state.
FluidFM addresses both challenges by touching a single living cell with nanoscale precision, keeping it alive whether we are reading its biology or rewriting its genome.
Applied to single-cell analysis, this enables Live-seq. We read a cell’s molecular state, apply a perturbation, and read the exact same living cell again. Direct cause and effect, not inferred correlation.
Applied to engineering, the same precision powers CellEDIT’s Impossible Genetic Edits. We deliver CRISPR directly into the nucleus of individual cells with maximum control while preserving the cell’s native state, enabling access to hard-to-transfect cells and large knock-ins beyond the reach of conventional methods.
Together, they create Cytosurge's Same-Cell Biology paradigm: engineering or perturbing a specific living cell, measuring the resulting molecular response, and tracking subsequent phenotypic changes over time, all in the same living cell.
THE STATUS QUO
Biology has a blind spot.
To measure a cell, you have to destroy it.
Most molecular profiling captures only a single moment in a cell’s life. Once measured, the cell is lost, along with the ability to observe what happens next.
To understand change over time, biology compares measurements across different cells and reconstructs what happened from those snapshots. Powerful, but ultimately inferred.
THE BREAKTHROUGH
The Same-Cell paradigm
What if you could return to the same living cell?
Cytosurge enables scientists to measure, perturb, and measure the same cell again without destroying it. Cellular uncertainty, turned into causal evidence.
Instead of inferring biological change across different cells, Same-Cell Biology follows the same living cell over time, revealing how it responds, changes, resists, or recovers.
> CYTOSURGE PERSPECTIVES
Our scientists share the thinking behind Same-Cell Biology: the evidence, the open questions, and the experiments reshaping what we can ask about living cells.
Start with Same-Cell Biology: Beyond the Single-Cell Snapshot by Tobias Beyer, Chief Scientific Officer.
THE MOMENT
Every AI model of biology is racing toward the same wall.
Models trained on endpoint data learn correlation. No amount of scale or compute turns correlation into causation. Cytosurge generates causal data by measuring the same living cell before and after a change.
WHERE WE ARE GOING
From platform to predictive biology.
Today’s platform and services are already at work, building toward what comes next.
1. PLATFORM
FluidFM OMNIUM
The technology platform enabling same-cell manipulation, sampling, and longitudinal measurement in living cells.
2. SERVICES
Live-seq + CellEDIT
Access Cytosurge capabilities as a service, from advanced cell engineering to same-cell sequencing and causal readouts.
3. FUTURE
The Virtual Cell
Build predictive models from longitudinal same-cell data to better understand how living cells respond to intervention.
OUR STORY
From ETH Zurich to Same-Cell Biology
Founded in 2009 at ETH Zurich, Cytosurge began with the idea of combining atomic force microscopy, nanotechnology, and microfluidics to interact with living cells with exceptional precision. That work led to the development of FluidFM, a technology for precise manipulation, sampling, and delivery in living cells while preserving cell viability. That foundation now supports instruments and services for longitudinal, same-cell measurement in living cells.
2009
Founded at ETH Zurich
FluidFM grows out of a decade of atomic force microscopy research.
2016
First peer-reviewed publications
Early studies demonstrate single-cell FluidFM injection and force spectroscopy.
2020
FluidFM OMNIUM launches
Live-seq, nano-injection, and force measurement become accessible for research labs.
2022
Live-seq validated in Nature
Peer-reviewed evidence shows that a living cell can be sampled, sequenced, and survive.
2024
CellEDIT launches
Advanced genome engineering becomes available as a service.
Today
Building the Same-Cell Biology platform
Cytosurge is expanding from cellular manipulation and measurement toward longitudinal, causal biology.
WHAT WE STAND FOR
The values behind the science.
How we work matters as much as what we build. These principles guide how we approach science, engineering, and the problems we solve with our partners.
CAUSALITY
Causality over correlation
We build tools and data that help reveal cause and effect, not just associations across different cells.
EVIDENCE
Evidence before assertion
Our scientific claims should be sourced, verified, and reproducible. Precision matters more than persuasion.
PRECISION
Precision that preserves life
Every measurement and edit is designed to preserve the cell and the biological state we are trying to understand.
PARTNERSHIP
Partners in impossible problems
We work alongside pharma, biotech, and academic teams on biological and engineering challenges that demand more than standard approaches.
OUR PEOPLE
The team shaping Same-Cell Biology
Engineers, biologist, and data scientist working together to understand how individual living cells respond before and after intervention, and turn that insight into better biological evidence.
Simon Egli
CEO
Leads Cytosurge’s strategy and team, turning the same-cell thesis into a working business.
Stephan Jud
CTO
Leads engineering and R&D, building the instruments and services that make same-cell biology practical.
Lorenz Malär
CFO
Oversees finance and operations, funding the path from today’s revenue to tomorrow’s AI platform.
Tobias Beyer
CSO
Leads scientific strategy, connecting Cytosurge’s technology to the biology questions that matter most.
Dario Ossola
CPO
Leads product across instruments and services, turning FluidFM capabilities into solutions.
BOARD OF DIRECTORS
Governance for the next phase of growth
Martin Gertsch
Chairman of the Board
Senior board and executive leader in life sciences, with a track record leading IPOs and M&A transactions and driving growth for start-ups and emerging companies.
Luba Greenwood, J.D
Member of the Board
CEO of Mwyngil Therapeutics and board member of MassBio. Previously founded and lead the venture fund at the Dana-Farber Cancer Institute.
Pascal Behr
Delegate of the Board
Cytosurge's co-founder, connecting the board to the company's scientific and technical vision.
THE NEXT CHAPTER
Building the future of Same-Cell Biology
Cytosurge is turning Same-Cell Biology from a new way of thinking into a practical way of doing biology.

